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The tumoricidal mechanisms of microbeam radiation therapy, and the more
recently proposed minibeam radiation therapy, for the treatment of brain
tumors are as yet unclear. Moreover, from among the various parameters of
beam geometry the impact of changing the beam width is unknown. In this study,
suppression of tumor growth in human glioma cells implanted in mice was
evaluated experimentally using microbeams of two different widths: a
conventional narrow beam (20 mm width, 100 mm center-to-center distance)
and a wide beam (100 mm width, 500 mm center-to-center distance). The tumor
growth ratio was compared and acute cell death was studied histologically. With
cross-planar irradiation, tumor growth was signiﬁcantly suppressed between
days 4 and 28 after 20 mm microbeam irradiation, whereas tumor growth was
suppressed, and not signiﬁcantly so, only between days 4 and 18 after 100 mm
microbeam irradiation. Immunohistochemistry using TUNEL staining showed
no increase in TUNEL-positive cells with either microbeam at 24 and 72 h post-
irradiation. The 20 mm microbeam was found to be more tumoricidal than the
100 mm microbeam, and the effect was not related to apoptotic cell death. The
underlying mechanism may be functional tissue deterioration rather than direct
cellular damage in the beam path.
Keywords: microbeam radiation therapy; narrow microbeam; wide microbeam;
co-planar microbeam; cross-planar microbeam.
1. Introduction
Microbeam radiation therapy (MRT), which was originally
introduced for the treatment of brain tumors by Slatkin et al.
(1992), uses a parallel array of microbeams, the so-called ‘co-
planar microbeam’, composed of high-intensity and highly
directional X-rays generated at a synchrotron radiation
facility. The principle of this treatment is based on the high
resistance of normal brain tissue to such irradiation. This
phenomenon was ﬁrst observed in experiments concerning the
biological effects of cosmic rays in the late 1950s. Zeman et al.
(1961) reported that a microscopic (25 mm) 22 MeV deuteron
beam required a dose of over 4000 Gy to kill cells in the beam
path in the mouse cortex, compared with a macroscopic
(1 mm) beam of only 140 Gy which destroyed all tissue in
its path.
Recently, Bra ¨uer-Krisch et al. (2010) comprehensively
reviewed the several in vivo studies of MRT that have been
carried out in rodents. These studies used various tumor cell
lines: glioma (Schu ¨ltke et al., 2008), gliosarcoma (Laissue et al.,
1998; Dilmanian et al., 2002; Smilowitz et al., 2006; Regnard et
al., 2008; Serduc et al., 2008, 2009a,b), squamous cell carci-
noma (Miura et al., 2006) and mammary tumor (Dilmanian et
al., 2003) cell lines. The implantation site was either brain
parenchyma or the ﬂanks near the hind legs. The results of
these studies provided clear evidence that MRTwas associated
with the suppression of tumor growth (Dilmanian et al., 2003;
Miura et al., 2006) and the extension of life of the rodents
implanted with tumors (Laissue et al., 1998; Dilmanian et al.,
2002; Smilowitz et al., 2006, 2008, 2009a,b; Regnard et al., 2008;
Schu ¨ltke et al., 2008).
In MRT, the geometry of the microbeam is deﬁned by the
parameters of beam width, center-to-center distance, peak
dose and valley dose (Fig. 1). In previous reports these para-
meters were in the range 25–90 mm, 50–300 mm, 150–900 Gy
and 12.1–40 Gy, respectively (Laissue et al., 1998; Dilmanian etal., 2002, 2003; Miura et al., 2006; Smilowitz et al., 2006;
Schu ¨ltke et al., 2008; Regnard et al., 2008; Serduc et al., 2008,
2009a,b). Most of these MRT studies used a narrow beam with
a width of around 30 mm. However, such a narrow beam can
be generated only by a large-scale synchrotron radiation
facility. Since the number of such facilities is limited, a more
practical beam for clinical purposes, the so-called ‘minibeam’
or ‘thick microbeam’, has recently been introduced for
radiation therapy (Dilmanian et al., 2006, 2008; Anschel et al.,
2007; Prezado et al., 2009). A parallel array of thick beams
(500–700 mm) is used to produce such a beam. However, the
tumoricidal effects obtained with different beam widths have
not yet been compared. It should also be emphasized that
previous studies have needed a high valley dose (12.1–40 Gy),
which might result in unacceptable irradiation levels in the
valley area. Indeed, Bra ¨uer-Krisch et al. (2010) state that the
valley dose is the most important determinant of normal tissue
damage in MRT.
The purpose of this study was to compare tumor growth in
human U251 glioma cells following microbeam radiation
treatment using microbeams of two different widths (20 mm
and 100 mm). For this purpose an adjustable collimator, which
enables modulation of the variable peak width, was used for
the ﬁrst time. To avoid any tumoricidal effect caused by valley
irradiation, we chose a relatively low dose of irradiation, with
the valley dose set as low as 4.8–9.6 Gy. We then assessed the
effect of MRT by measuring the volume of tumors irradiated
over time and recording the histological ﬁndings of tumors in
the acute phase after irradiation.
2. Materials and methods
2.1. Experimental groups
Thirty-six mice implanted with tumors were divided into a
MRT-treated group (n = 28) and a control group (n = 8). The
MRT-treated group was then further divided into four
subgroups: (i) a co-planar MRT group where microbeams
100 mm wide with a 500 mm center-to-center distance were
used (‘co-planar 100’; n = 8); (ii) a cross-planar MRT group
where microbeams 100 mm wide with a 500 mm center-to-
center distance were used (‘cross-planar 100’; n = 8); (iii) a
cross-planar MRT group where microbeams 20 mm wide with
a 100 mm center-to-center distance were used (‘cross-planar
20’; n= 6); and (iv) a repeated cross-planar MRT group where
microbeams 100 mm wide with a 500 mm center-to-center
distance were delivered once a day for two days (‘cross-planar
100  2’; n = 6).
2.2. Preparation of tumor model
All procedures involving animals were approved by the
Animal Care and Use Review Committee of Kobe University
Graduate School of Medicine. Male ﬁve-week-old nude mice
(BALB/cAJc1-nu/nu) weighing 20–25 g (Clea Japan, Osaka,
Japan) were housed in an approved speciﬁc pathogen-free
facility at Kobe University in accordance with Laboratory
Animal Resources Commission standards. Appropriate care
was taken to minimize animal discomfort, and appropriate
sterile surgical techniques were utilized for tumor implanta-
tion and drug administration. U251 human glioma cells were
maintained in Dullbecco’s modiﬁed Eagle’s medium
containing glutamine, 10% fetal bovine serum, penicillin/
streptomycin, and grown at 310 K in a 5% CO2 incubator. Ten
days before MRT, the tumor cells were concentrated to 6 
10
6 per 200 ml and implanted subcutaneously into the ﬂanks
near the hind legs of mice anesthetized with halothane inha-
lation.
2.3. Radiation source
MRTwas performed at SPring-8, a large-scale synchrotron
radiation facility in Japan. The radiation source was generated
at the white X-ray bending-magnet beamline BL28B2. The
radiation beam traveled in a vacuum transport tube with
minimized air scattering of the primary beam. X-rays passed
from the vacuum tube into the atmosphere through a beryl-
lium vacuum window, then into a 2.0 m helium beam path
consisting of an aluminium tube and a thin aluminium helium
window located 42 m from the synchrotron radiation output.
The sample positioning system was placed 2.5 m from the thin
aluminium window. A 3 mm-thick copper ﬁlter was inserted
into the beam to remove the low-energy component. The
X-ray spectrum was in the range 50–200 keV, peaking at
around 90 keV. The air kerma rate of the broad beam was
measured with a free-air ionization chamber. The electrode
gap was 85 mm, which kept the electron escape fraction from
the chamber below 3%, at 50–200 keV (Nariyama et al., 2004).
Near current saturation was obtained by applying a voltage of
9.5 kV.
2.4. Collimator and irradiation
MRTwas performed with the aid of an adjustable single-slit
collimator which enabled a variable spatial fractionation of
the X-ray beam (Fig. 2a). The microbeam width was equal to
the distance between two plates of tantalum. The center-to-
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Figure 1
Schematic geometry of microbeam arrays used in MRT.center distance between one beam and the next beam was
determined by horizontally moving the platform holding the
experimental animal. An anesthetized mouse (sodium
pentobarbital; 0.5 mg per 10 g of body weight, i.p.) was placed
on the platform in the prone position lying on a styrol box. The
hind leg with the tumor was immobilized with a plastic ring in
a direction perpendicular to the microbeams. For the ‘co-
planar MRT’ irradiation, mice received a single irradiation
treatment in the prone position (Fig. 2b); for the ‘cross-planar
MRT’, mice received staged irradiation, ﬁrst receiving irra-
diation as performed for ‘co-planar MRT’, followed by a
second irradiation in the vertical position by rotating the axis
by 90 so that the head was up (Fig. 2c). The radiation ﬁeld was
15 mm wide and 15 mm high.
The spatial dose distribution was examined using
GafChromic ﬁlm HD-810 (ISP Technologies, NJ, USA) as
described previously (Nariyama et al., 2009) (Figs. 2d–2f). The
optical density of the irradiated ﬁlms was measured with a
digital microscope through bandpass ﬁlters, and converted to
dose using a calibration curve obtained in advance. The
bandpass ﬁlters of 601 and 668 nm were used to attain the
straight line for the calibration curve and increase the sensi-
tivity and accuracy; the former was used for the peak dose and
the latter for the valley dose.
2.5. Dose rate setting
The air kerma rate was preset at 140 Gy s
1 at the hutch.
With the newly designed adjustable collimeter the X-ray peak
dose rates were found to be 124 Gy s
1 and 111 Gy s
1 for the
100 mm and 20 mm microbeams, respectively (Figs. 3a and 3b).
The dose rate at a distance of 250 mm from the center of the
100 mm microbeam was 4.8 Gy s
1 (Fig. 3a), while that at a
distance of 50 mm from the center of the 20 mm microbeam
was 4.1 Gy s
1 (Fig. 3b). The duration of irradiation was 1 s, in
order to keep the valley dose low while ensuring sufﬁcient cell
damage at peak dose. The valley dose of the cross-planar
microbeam was double that of the co-planar microbeam at the
same peak dose. For ‘co-planar 100’, ‘cross-planar 100’ and
‘cross-planar 20’, the cumulative valley dose was 4.8 Gy,
9.6 Gy and 8.2 Gy, respectively.
2.6. Evaluation of tumor growth
Tumor volume was measured for the two perpendicular
diameters (X, Y) and thickness (Z) two to three times per
week for one month after irradiation, by a technical assistant
who was not informed of the treatment protocol. Tumor
volume (V) was estimated using the formula V = X  Y  Z 
0.52 as described previously (Shichiri et al., 2009). The relative
growth ratio was deﬁned as V(at individual measurement
point)/V(at irradiation) and analyzed statistically.
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Figure 2
(a) An adjustable single-slit collimator which enables modulation of the
variable peak width. (b) For co-planar microbeam irradiation, mice were
treated with a single set of irradiation in the prone position. (c) For cross-
planar microbeam irradiation, mice were irradiated in stages by means of
90 rotation about the axis parallel to the microbeams. (d–f) The spatial
dose distribution was conﬁrmed using GafChromic ﬁlm for ‘co-planar
100’ (d), ‘cross-planar 100’ (e) and ‘cross-planar 20’ (f). Scale bar: 1 mm.
Figure 3
The spatial dose distribution was measured using GafChromic ﬁlm in a
100 mm-wide microbeam (a) and 20 mm-wide microbeam (b). The peak
dose was 130 Gy for both.2.7. Histopathology
Forty-two mice were used for histopathological analysis. To
determine the response to MRT, mice from the ‘co-planar
100’, ‘cross-planar 100’ and ‘cross-planar 20’ groups (excluding
the ‘cross-planar 100  2’ group) were sacriﬁced at 24 and 72 h
after irradiation (for all groups n = 3 for each time point).
Three tumor-bearing mice that did not receive irradiation
were sacriﬁced as controls at each of the same time points. To
examine rapid pathological changes in the early post-irradia-
tion phase, additional mice in the ‘cross-planar 100’ and ‘cross-
planar 20’ groups were sacriﬁced at 3, 6 and 12 h after irra-
diation (n = 3 for each time point). After the mice had been
deeply anesthetized, tumors were removed and ﬁxed with 4%
paraformaldehyde in phosphate-buffered saline (pH 7.4) for
24 h. Tumor tissue was cut along the horizontal plane
perpendicular to the microbeams, embedded in parafﬁn,
processed to yield 4 mm-thick sections, and stained with
hematoxylin and eosin (HE).
Sections from the ‘cross-planar 100’ and ‘cross-planar 20’
groups obtained 24 and 72 h after irradiation as well as
sections from the control mice were also used for detecting
apoptosis by using the terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labeling (TUNEL) technique. The
TUNEL reaction was performed with the ApoMark DNA
Fragmentation Apoptosis Detection Kit (Exalpha Biologicals,
Shirley, MA, USA) according to the manufacturer’s instruc-
tions. The rate of apoptosis, calculated as the percentage of
TUNEL-positive cells out of 1000 cells, was determined for 12
random tumor sections taken from three different tumors in
each group.
2.8. Statistics
A one-way ANOVA was used to examine within-group
differences in the tumor growth ratio at the individual time
points post-irradiation and the difference in percentage of
TUNEL-positive cells. For comparison between the groups, an
additional post-hoc test was performed using the Turkey–
Kramer method. The threshold for statistical signiﬁcance was
set at p < 0.05. Values are expressed in the ﬁgures as mean 
standard deviation (SD).
3. Results
3.1. Tumor growth
At irradiation the mean tumor volume (mm
3) for the
control, ‘co-planar 100’, ‘cross-planar 100’, ‘cross-planar 20’
and ‘cross-planar 100  2’ groups were 43.8  17.1, 37.1 
14.5, 34.8  10.6, 34.7  7.1 and 40.6  13.3 (mean  SD),
respectively. As shown in Fig. 4, the groups showed suppres-
sion from lowest to highest in the order of ‘co-planar 100’,
‘cross-planar 100’, ‘cross-planar 20’ and ‘cross-planar 100  2’.
At 28 days after irradiation, tumor growth ratios of the
control, ‘co-planar 100’, ‘cross-planar 100’, ‘cross-planar 20’
and ‘cross-planar 100  2’ groups reached 71.5  68.7, 32.2 
19.6, 22.0  16.2, 9.9  7.9 and 9.6  5.2, respectively (Fig. 4).
When compared with the control group, the ‘co-planar 100’
group showed signiﬁcant suppression of tumor growth (p <
0.05) at 4, 7 and 10 days post-irradiation, the ‘cross-planar 100’
group showed signiﬁcant suppression at 4, 7, 10, 14 and 18 days
post-irradiation, and the ‘cross-planar 20’ and ‘cross-planar
100  2’ showed signiﬁcant suppression at 4, 7, 10, 14, 18, 21,
25 and 28 days post-irradiation. Thus, the ‘cross-planar 20’
group showed longer tumor growth suppression than the
‘cross-planar 100’ group, and the ‘cross-planar 100  2’ group
showed suppression comparable with that of the ‘cross-planar
20’ group.
3.2. Histological study
HE-stained sections of the non-irradiated control mice
showed a large and dense cellular mass with marked pleo-
morphism. Endothelial hypertrophy was not evident, a few
necrotic regions were located in the center of mass, and typical
palisading cells were seen around the necrotic lesion (Fig. 5a).
Irradiated HE-stained sections showed dark stripes along the
beam path at low magniﬁcation at 24 h post-irradiation. The
path was clearly seen in the ‘co-planar 100’, ‘cross-planar 100’
and ‘cross-planar 20’ groups (Figs. 5b,5 c,5 e), and a dense
closely compacted cellular arrangement was observed on the
path (Figs. 5d,5 f). The nuclei were more darkly stained than
the nuclei of non-irradiated tumors. There were no micro-
hemorrhages or non-viable cells in the area between the
peaks. The path itself in the ‘cross-planar 20’ group was
narrow and faint, and the area between the peaks showed
intercellular edema. The size of the necrotic lesion differed in
each of the treated tumors but no small cavitations that would
indicate new pathological developments were seen (Figs. 5d,
5f). The dark stripes along the beam path remained at 72 h
post-irradiation (Figs. 5g,5 h). A comparison of the rapid
pathological changes in the early post-irradiation phase in the
‘cross-planar 100’ and ‘cross-planar 20’ groups revealed darkly
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Figure 4
The relative growth ratios at various measurement time points during a
28 day period compared with measurements obtained at irradiation for
‘control’, ‘co-planar 100’, ‘cross-planar 100’, ‘cross-planar 20’ and ‘cross-
planar 100  2’. The asterisks indicate p < 0.05 when compared with the
control group at a given time point.stained nuclei on the beam path in both groups at 6 h post-
irradiation (Fig. 6).
TUNEL results showed few apoptotic regions in all of the
irradiated ﬁelds (Fig. 7). The average percentage of TUNEL-
positive cells was 0.56  0.23 in the control group and 0.54 
0.11 in the ‘cross-planar 100’ group at 24 h post-irradiation,
0.53  0.17 in the ‘cross-planar 100’ group at 72 h, 0.84  0.37
in the ‘cross-planar 20’ group at 24 h, and 0.80  0.42 in the
‘cross-planar 100’ group at 72 h (Fig. 8). The percentage was
not signiﬁcantly different between any two groups.
4. Discussion
We studied the effects of MRTwith a greater beam width and
center-to-center distance than reported previously in an
animal model implanted with U251 human glioma cells. We
demonstrated that microbeams with a greater beam width and
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Figure 6
HE-stained sections 3, 6 and 12 h after irradiation with ‘cross-planar 100’
and ‘cross-planar 20’. Scale bar: 500 mm.
Figure 7
TUNEL staining of the sections irradiated with ‘cross-planar 100’ and
‘cross-planar 20’ showing few apoptotic regions in any of the irradiated
ﬁelds at low magniﬁcation. Scale bar: 500 mm.
Figure 5
HE-stained sections of control (a), and 24 h after irradiation with ‘co-
planar 100’ (b), ‘cross-planar 100’ (c–d) and ‘cross-planar 20’ (e–f),
showing dark stripes along the beam path. The dark stripes remained 72 h
after irradiation with ‘cross-planar 100’ (g) and ‘cross-planar 20’ (h).
Arrows: microbeam path. Scale bar for (a), (b), (c), (e), (g), (h): 500 mm;
for (d), (f): 100 mm.center-to-center distance (100 mm and 500 mm, respectively)
than reported previously (25–90 mm and 50–300 mm, respec-
tively) produced moderate tumor growth suppression when
applied in a cross-planar pattern, and that narrow microbeams
with a width of 20 mm showed longer tumor growth suppres-
sion than microbeams with a width of 100 mm. These ﬁndings
indicate that the tumor suppression effect of X-ray irradiation
does not depend on the total amount of irradiated dose alone.
Differences in spatial distribution also clearly affect tumor
growth suppression and a narrow beam is more effective than
a wide beam for MRT.
With regard to the mechanisms of tumor growth suppres-
sion, it could be suggested that the bystander effect of MRT
affects tumor cells in the valley zone. However, our previous
in vitro study using C6 glioma cells (Kashino et al., 2009)
demonstrated that such an effect is not sufﬁcient to explain
in vivo tumor growth suppression. At least, MRT-treated cells
cultured in a dish do not exactly mimic the characteristics of
MRT-treated cells in vivo.
Another possibility is that the tumoricidal effect of MRT
results from the high biologically hazardous dosing of the
valley zone, in other words, the background irradiation of all
the targeted areas. To clarify this point we reviewed all
previous MRT studies using animals reported in the literature
(Table 1). Regardless of differences in tumor cell line, irra-
diation geometry, beam width, center-to-center distance or
peak dose, we found that the valley doses used in these studies
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Table 1
Summary of previously reported experiments of MRTwith animals.
Author; journal; year Tumor cell line
Implantation
site
Irradiation
geometry
Beam
width
(mm)
Center-to-
center
distance
(mm)
Peak
dose (Gy)
Valley
dose (Gy)
Evaluation
criteria
Laissue et al.;
Int. J. Cancer;
1998
9L gliosarcoma Brain Co-planar 25 100 625 Survival rate
Orthogonal 25 100 312.5 Tumor size
Orthogonal 25 100 625 Normal brain damage
Dilmanian et al.;
Neuro-Oncology;
2002
9L gliosarcoma Brain Co-planar 27 50 150–300 20–40 Survival rate
Co-planar 27 75 250–500 17–33 MRI (tumor size,
normal brain damage) Co-planar 27 100 500 19
Dilmanian et al.;
Radiat. Res.;
2003
Murine EMT-6
mammary
carcinoma
Hind leg Co-planar 90 300 800–1900 16–38 Tumor size
Cross-planar 90 300 410–650 16–26 Normal tissue toxicity
Smilowitz et al.;
J. Neuro-oncology;
2006
9L gliosarcoma Brain Co-planar 25 211 625 Survival rate
Miura et al.;
Br. J. Radiol.;
2006
Human squamaous
cell carcinoma
Hind leg Orthogonal 35 200 442 Tumor size
Orthogonal 35 200 625 Normal tissue toxicity
Orthogonal 35 200 884
Orthogonal 70 200 442
Regnard et al.;
Phys. Med. Biol.;
2008
9L gliosarcoma Brain Co-planar 25 100 625 36 Survival rate
Co-planar 25 200 625 12.1 Clinical sign
Body weight pattern
Serduc et al.;
Phys. Med. Biol.;
2008
9L gliosarcoma Brain Orthogonal 25 211 500 24 Survival rate
MRI (blood volume,
vessel size)
Schu ¨ltke; Eur. J.
Radiol.; 2008
F98 glioma Brain Orthogonal 25 211 350 Survival rate
C6 glioma
Serduc et al.;
Phys. Med. Biol.;
2009
9L gliosarcoma Brain Orthogonal 25 211 860 36 Survival rate
Orthogonal 50 211 480 36
Orthogonal 75 211 320 36
Serduc et al.;
J. Synchrotron
Rad.;
2009
9L gliosarcoma Brain Three fractions
through three
orthogonal
ports at 24 h
intervals
50 211 400 (two
directions)
15 per
exposure
Survival rate
360 (one
direction)
Memory function
This work Human U251
glioma
Hind leg Co-planar 100 500 124 4.8 Tumor size
Cross-planar 100 500 124 9.6
Cross-planar 20 100 111 8.2
Figure 8
The percentages of TUNEL-positive cells are summarized.were relatively high (12.1–40 Gy) and this has a direct effect
on tumor cell growth in the valley zone. In particular, this dose
could be critical when radiosensitive tumor cells are used. In
previous studies of experimental radiosurgery on malignant
brain tumors using a gamma knife unit the 50% marginal dose
was 15–35 Gy, and cellular damage was histologically proven
and survival rate signiﬁcantly improved (Kondziolka et al.,
1992; Niranjan et al., 2000, 2003; Nakahara et al., 2001). To
minimize the direct effect in the valley zone, our study used a
lower dose (4.8–9.6 Gy) than used previously. Since a radia-
tion dose <10 Gy has never been reported to affecttumor cells
in vivo, tumor growth suppression in the present study is
unlikely to have resulted from the valley dose.
A double-strand break of DNA is fundamentally a direct
acute cellular response to radiation and probably occurs in the
peak area of both the wider (100 mm) and narrower (20 mm)
microbeam. One unexpected result of the present study was
that no signiﬁcant change in the rate of apoptotic cells was
detected by TUNEL staining. In another study it was found
that a 35–70 Gy dose administered with a gamma knife unit
did induce apoptotic cell death of 9L gliosarcoma between
6 and 48 h post-irradiation (Witham et al., 2005) in a treated
area 4 mm in diameter. However, in our study, microbeams of
the order of 20 to 100 mm did not result in apoptotic tumor cell
death even in the peak zone. No tissue death was induced
either at the cellular or tissue level, because the necrotic area
in each subgroup hardly changed after MRT. Therefore, the
mechanism of tumor growth suppression in our study is likely
to be the induction of lower cell proliferation.
Another possible mechanism of in vivo tumor suppression
may be alteration of microvascular structures. Serduc et al.
(2008) hypothesized that the tumoral vessel injury caused by
MRT mainly affected tumor growth suppression, but they
found no signiﬁcant microvascular components, at least under
their experimental conditions using 9L gliosarcoma implanted
into the brain. We believe that further histological or func-
tional studies of neovascularizing tumor vessels are required
to identify the tumoricidal mechanism of MRT.
Recently, radiation therapy using a parallel array of thick
beams (500–700 mm) with the same separation distance
between beams, the so-called ‘minibeam’ or ‘thick microbeam’
therapy, has been recommended (Dilmanian et al., 2006, 2008;
Anschel et al., 2007; Prezado et al., 2009). Dilmanian et al.
(2008) reported that this irradiation method at a peak dose of
170 Gy did not induce neurological deﬁcits in rats. Although
the biological mechanisms of the effects of such minibeams on
tumor cells have not been thoroughly studied, our study
demonstrated that the wide MRTof ‘cross-planar 100’ was as
effective as the narrow MRT of ‘cross-planar 20’ when the
wide MRTwas applied once a day for two days. We therefore
think that temporal fractionated MRT is useful for ampliﬁ-
cation of the tumoricidal effect of MRT.
Maintaining the proper balance between the tumoricidal
and adverse effects of MRT on normal brain tissue and
function is a challenging aspect in the reﬁnement of the
therapy. Regnard et al. (2008) reported on the effects of MRT
by comparing the results obtained with 25 mm-wide co-planar
beams with a 200 mm or 100 mm center-to-center distance.
They found that MRTwith a 200 mm center-to-center distance
was superior in terms of sparing healthy tissue but that life-
span was longer with a 100 mm center-to-center distance.
Schu ¨ltke et al. (2008) reported that no memory dysfunction
was detected in object recognition tests for rats treated with
brain irradiation using 25 mm-wide microbeams with a 200 mm
center-to-center distance and a skin entrance dose of 350 Gy.
Whether wide MRTof 100 mm may affect normal brain tissue
or function remains to be determined in future research.
In conclusion, MRT using a 100 mm-wide microbeam with
500 mm center-to-center distance resulted in moderate tumor
growth suppression, although MRT using a 20 mm-wide
microbeam resulted in longer tumor growth suppression. The
biological mechanism underlying these ﬁndings is still unclear:
it may involve functional tissue deterioration rather than
direct cellular damage in the beam path. Further comparative
experimental studies using both wide and narrow microbeams
are warranted to determine the potential of MRT for clinical
purposes.
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Research Institute (Proposals No. 2008B1627, 2009A1281 and
2009B1614).
References
Anschel, D. J., Romanelli, P., Benveniste, H., Foerster, B., Kalef-Ezra,
J., Zhong, Z. & Dilmanian, F. A. (2007). Minim. Invas. Neurosurg.
50, 43–46.
Bra ¨uer-Krisch, E., Serduc, R., Siegbahn, E. A., Le Duc, G., Prezado,
Y., Bravin, A., Blattmann, H. & Laissue, J. A. (2010). Mutat. Res.
704, 160–166.
Dilmanian, F. A., Button, T. M., Le Duc, G., Zhong, N., Pena, L. A.,
Smith, J. A., Martinez, S. R., Bacarian, T., Tammam, J., Ren, B.,
Farmer, P. M., Kalef-Ezra, J., Micca, P. L., Nawrocky, M. M.,
Niederer, J. A., Recksiek, F. P., Fuchs, A. & Rosen, E. M. (2002).
Neuro-Oncology, 4, 26–38.
Dilmanian, F. A., Morris, G. M., Zhong, N., Bacarian, T., Hainfeld,
J. F., Kalef-Ezra, J., Brewington, L. J., Tammam, J. & Rosen, E. M.
(2003). Radiat. Res. 159, 632–641.
Dilmanian, F. A., Romanelli, P., Zhong, Z., Wang, R., Wagshul, M. E.,
Kalef-Ezra, J., Maryanski, M. J., Rosen, E. M. & Anschel, D. J.
(2008). Eur. J. Radiol. 68, S129–S136.
Dilmanian, F. A., Zhong, Z., Bacarian, T., Benveniste, H., Romanelli,
P., Wang, R., Welwart, J., Yuasa, T., Rosen, E. M. & Anschel, D. J.
(2006). Proc. Natl Acad. Sci. USA, 103, 9709–9714.
Kashino, G., Kondoh, T., Nariyama, N., Umetani, K., Ohigashi, T.,
Shinohara, K., Kurihara, A., Fukumoto, M., Tanaka, H., Maru-
hashi, A., Suzuki, M., Kinashi, Y., Liu, Y., Masunaga, S., Watanabe,
M. & Ono, K. (2009). Int. J. Radiat. Oncol. Biol. Phys. 74, 229–236.
Kondziolka, D., Lunsford, L. D., Claassen, D., Pandalai, S., Maitz, A.
H. & Flickinger, J. C. (1992). Neurosurgery, 31, 280–287.
Laissue, J. A., Geiser, G., Spanne, P. O., Dilmanian, F. A., Gebbers,
J. O., Geiser, M., Wu, X. Y., Makar, M. S., Micca, P. L., Nawrocky,
research papers
J. Synchrotron Rad. (2011). 18, 671–678 Atsushi Uyama et al.  Microbeam radiation therapy for human glioma 677M. M., Joel, D. D. & Slatkin, D. N. (1998). Int. J. Cancer, 78, 654–
660.
Miura, M., Blattmann, H., Bra ¨uer-Krisch, E., Bravin, A., Hanson,
A. L., Nawrocky, M. M., Micca, P. L., Slatkin, D. N. & Laissue, J. A.
(2006). Br. J. Radiol. 79, 71–75.
Nakahara, N., Okada, H., Witham, T. F., Attanucci, J., Fellows, W. K.,
Chambers, W. H., Niranjan, A., Kondziolka, D. & Pollack, I. F.
(2001). J. Neurosurg. 95, 984–989.
Nariyama, N., Kishi, N. & Ohnishi, S. (2004). Nucl. Instrum. Methods
Phys. Res. A, 524, 324–331.
Nariyama, N., Ohigashi, T., Umetani, K., Shinohara, K., Tanaka, H.,
Maruhashi, A., Kashino, G., Kurihara, A., Kondob, T., Fukumoto,
M. & Ono, K. (2009). Appl. Radiat. Isot. 67, 155–159.
Niranjan, A., Moriuchi, S., Lunsford, L. D., Kondziolka, D.,
Flickinger, J. C., Fellows, W., Rajendiran, S., Tamura, M., Cohen,
J. B. & Glorioso, J. C. (2000). Mol. Ther. 2, 114–120.
Niranjan, A., Wolfe, D., Tamura, M., Soares, M. K., Krisky, D. M.,
Lunsford, L. D., Li, S., Fellows-Mayle, W., DeLuca, N. A., Cohen,
J. B. & Glorioso, J. C. (2003). Mol. Ther. 8, 530–542.
Prezado, Y., Renier, M. & Bravin, A. (2009). J. Synchrotron Rad. 16,
582–586.
Regnard, P., Le Duc, G., Bra ¨uer-Krisch, E., Tropre `s, I., Siegbahn, E.
A., Kusak, A., Clair, C., Bernard, H., Dallery, D., Laissue, J. A. &
Bravin, A. (2008). Phys. Med. Biol. 53, 861–878.
Schu ¨ltke, E., Juurlink, B. H., Ataelmannan, K., Laissue, J., Blattmann,
H., Bra ¨uer-Krisch, E., Bravin, A., Minczewska, J., Crosbie, J.,
Taherian, H., Frangou, E., Wysokinsky, T., Chapman, L. D.,
Griebel, R. & Fourney, D. (2008). Eur. J. Radiol. 68, S142–
S146.
Serduc, R., Bouchet, A., Bra ¨uer-Krisch, E., Laissue, J. A., Spiga, J.,
Sarun, S., Bravin, A., Fonta, C., Renaud, L., Boutonnat, J.,
Siegbahn, E. A., Esteve, F. & Le Duc, G. (2009a). Phys. Med.
Biol. 54, 6711–6724.
Serduc, R., Bra ¨uer-Krisch, E., Bouchet, A., Renaud, L., Brochard, T.,
Bravin, A., Laissue, J. & Le Duc, G. (2009b). J. Synchrotron Rad.
16, 587–590.
Serduc, R., Christen, T., Laissue, J., Farion, R., Bouchet, A., Sanden,
B., Segebarth, C., Bra ¨uer-Krisch, E., Le Duc, G., Bravin, A., Re ´my,
C. & Barbier, E. L. (2008). Phys. Med. Biol. 53, 3609–3622.
Shichiri, M., Fukai, N., Kono, Y. & Tanaka, Y. (2009). Cancer Res. 69,
4760–4768.
Slatkin, D. N., Spanne, P., Dilmanian, F. A. & Sandborg, M. (1992).
Med. Phys. 19, 1395–1400.
Smilowitz, H. M., Blattmann, H., Bra ¨uer-Krisch, E., Bravin, A., Di
Michiel, M., Gebbers, J. O., Hanson, A. L., Lyubimova, N., Slatkin,
D. N., Stepanek, J. & Laissue, J. A. (2006). J. Neurooncol. 78, 135–
143.
Witham, T. F., Okada, H., Fellows, W., Hamilton, R. L., Flickinger,
J. C., Chambers, W. H., Pollack, I. F., Watkins, S. C. & Kondziolka,
D. (2005). Stereotact. Funct. Neurosurg. 83, 17–24.
Zeman, W., Curtis, H. J. & Baker, C. P. (1961). Radiat. Res. 15, 496–
514.
research papers
678 Atsushi Uyama et al.  Microbeam radiation therapy for human glioma J. Synchrotron Rad. (2011). 18, 671–678